Xin Lang Cai Jing·2025-11-04 01:59Core Viewpoint - Kailaiying's stock price has experienced fluctuations, with a year-to-date increase of 29.29% but a recent decline of 11.92% over the past 60 days, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Kailaiying achieved a revenue of 4.63 billion yuan, representing a year-on-year growth of 11.82%. The net profit attributable to shareholders was 800 million yuan, reflecting a growth of 12.66% [2]. - Since its A-share listing, Kailaiying has distributed a total of 2.405 billion yuan in dividends, with 1.701 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of Kailaiying's shareholders reached 60,100, an increase of 45.37% compared to the previous period. The average circulating shares per person remained at 0 shares [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]. Market Activity - On November 4, Kailaiying's stock price fell by 2.02%, trading at 96.96 yuan per share, with a total market capitalization of 34.963 billion yuan. The stock saw a net outflow of 3.0292 million yuan in principal funds [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on August 8, where it recorded a net buy of -180 million yuan [1]. Business Overview - Kailaiying Pharmaceutical Group, established on October 7, 1998, and listed on November 18, 2016, primarily provides CMO pharmaceutical outsourcing services. The revenue composition includes 76.19% from small molecule CDMO solutions and 23.71% from emerging services [1][2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing [2].